MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/ccd.21925

Медицинская библиотека · Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2009

Multivessel drug-eluting stenting and impact of diabetes mellitus--a report from the EVENT registry.

Novack Victor, Tsyvine Daniel, Cohen David J, Pencina Michael, Dubin Joseph, Dehghani Hossein, Kleiman Neal S, Cutlip Donald E

Сравнительное исследованиеСтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

OBJECTIVES

To compare clinical outcomes in patients with and without diabetes after multivessel percutaneous coronary intervention (PCI).

BACKGROUND

Diabetes is associated with significantly worse outcomes after multivessel PCI and coronary bypass surgery is recommended as the preferred option for these patients.

METHODS AND

RESULTS

The Evaluation of Drug Eluting Stents and Ischemic Events registry is a multicenter evaluation of acute and 1 year outcomes in unselected patients undergoing PCI since approval of drug-eluting stents (DES). Major adverse cardiac events (MACE) were defined as all cause mortality, myocardial infarction, or repeat revascularization and rate was estimated by Kaplan-Meier method and compared using log-rank. The independent correlates of MACE were determined using Cox proportional hazards regression. Of 4,819 nonemergency native coronary DES procedures, 1,595 (33.1%) were in patients with diabetes and 722 (11.7%) involved >1 vessel. Of patients undergoing multivessel procedures, diabetes was present in 256 (35.5%). One year after multivessel PCI, MACE was similar for patients with or without diabetes (22.3% versus 21.2%, log-rank test P = 0.85). The independent correlates of 1 year MACE were female sex (Hazard ratio [HR], 1.58, 95% CI 1.14-2.20), ejection fraction (HR 0.74 per group [<25%, 26-35%, 36-50%, and >50%], 95%CI 0.59-0.94) and number of stents (HR 1.20 per stent, 95%CI 1.04-1.38) but not diabetes (HR 1.00, 95% CI 0.71-1.39).

CONCLUSIONS

Multivessel DES is performed commonly in patients with diabetes with outcomes at 1 year similar to patients without diabetes. Longer follow-up is required to more fully evaluate the safety and effectiveness of this strategy.

Для цитирования: Novack Victor, Tsyvine Daniel, Cohen David J, Pencina Michael, Dubin Joseph, Dehghani Hossein, Kleiman Neal S, Cutlip Donald E. Multivessel drug-eluting stenting and impact of diabetes mellitus--a report from the EVENT registry.. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. 2009. DOI: 10.1002/ccd.21925.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.